Responses
Regular and young investigator award abstracts
Clinical trials in progress
419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.